

Ryohei Katayama

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1146500/ryohei-katayama-publications-by-citations.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

61
papers

8,846
citations

35
h-index

64
g-index

64
ext. papers

10,191
ext. citations

10.7
avg, IF

5.53
L-index

#	Paper	IF	Citations
61	ROS1 rearrangements define a unique molecular class of lung cancers. <i>Journal of Clinical Oncology</i> , 2012 , 30, 863-70	2.2	1170
60	Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. <i>Science Translational Medicine</i> , 2012 , 4, 120ra17	17.5	948
59	Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. <i>Cancer Discovery</i> , 2016 , 6, 1118-1133	24.4	648
58	The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. <i>Cancer Discovery</i> , 2014 , 4, 662-673	24.4	591
57	Patient-derived models of acquired resistance can identify effective drug combinations for cancer. <i>Science</i> , 2014 , 346, 1480-6	33.3	507
56	Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 7535-40	11.5	445
55	ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2013 , 19, 4273-81	12.9	411
54	RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. <i>Nature Communications</i> , 2015 , 6, 6377	17.4	358
53	Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F. <i>New England Journal of Medicine</i> , 2016 , 374, 54-61	59.2	334
52	PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models. <i>Cancer Cell</i> , 2015 , 28, 70-81	24.3	301
51	Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4953-60	2.2	296
50	Acquired resistance to crizotinib from a mutation in CD74-ROS1. <i>New England Journal of Medicine</i> , 2013 , 368, 2395-401	59.2	268
49	Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. <i>Clinical Cancer Research</i> , 2014 , 20, 5686-96	12.9	227
48	Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels. <i>Cancer Research</i> , 2008 , 68, 5076-85	10.1	217
47	Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. <i>Nature Communications</i> , 2017 , 8, 14768	17.4	197
46	Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine. <i>Clinical Cancer Research</i> , 2015 , 21, 2227-35	12.9	188
45	Apollon ubiquitinates SMAC and caspase-9, and has an essential cytoprotection function. <i>Nature Cell Biology</i> , 2004 , 6, 849-60	23.4	187

44	Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition. <i>Cancer Research</i> , 2013 , 73, 3087-96	10.1	164
43	Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 166-74	12.9	145
42	Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer. <i>Journal of Experimental Medicine</i> , 2019 , 216, 982-1000	16.6	105
41	P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer. <i>EBioMedicine</i> , 2016 , 3, 54-66	8.8	97
40	Transforming growth factor- β decreases the cancer-initiating cell population within diffuse-type gastric carcinoma cells. <i>Oncogene</i> , 2011 , 30, 1693-705	9.2	66
39	The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models. <i>Nature Communications</i> , 2019 , 10, 3604	17.4	65
38	Dofequidar fumarate sensitizes cancer stem-like side population cells to chemotherapeutic drugs by inhibiting ABCG2/BCRP-mediated drug export. <i>Cancer Science</i> , 2009 , 100, 2060-8	6.9	62
37	Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance. <i>EBioMedicine</i> , 2019 , 41, 105-119	8.8	60
36	Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers. <i>Molecular Cancer Therapeutics</i> , 2017 , 16, 2130-2143	6.1	60
35	Complex N-glycosylated form of nicastrin is stabilized and selectively bound to presenilin fragments. <i>FEBS Letters</i> , 2002 , 520, 117-21	3.8	56
34	AP-1-Dependent miR-21 expression contributes to chemoresistance in cancer stem cell-like SP cells. <i>Oncology Research</i> , 2010 , 19, 23-33	4.8	53
33	Casein kinase 2-interacting protein-1, a novel Akt pleckstrin homology domain-interacting protein, down-regulates PI3K/Akt signaling and suppresses tumor growth in vivo. <i>Cancer Research</i> , 2007 , 67, 9666-76	10.1	53
32	Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2017 , 16, 752-762	6.1	52
31	Tivantinib (ARQ 197) exhibits antitumor activity by directly interacting with tubulin and overcomes ABC transporter-mediated drug resistance. <i>Molecular Cancer Therapeutics</i> , 2014 , 13, 2978-90	6.1	46
30	Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of Mutation Status. <i>Cancer Research</i> , 2019 , 79, 1658-1670	10.1	44
29	Drug resistance in anaplastic lymphoma kinase-rearranged lung cancer. <i>Cancer Science</i> , 2018 , 109, 572-580	8.0	39
28	Cellular FLIP inhibits beta-catenin ubiquitylation and enhances Wnt signaling. <i>Molecular and Cellular Biology</i> , 2004 , 24, 8418-27	4.8	39
27	Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response. <i>Leukemia</i> , 2018 , 32, 2590-2603	10.7	36

26	High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer. <i>Lung Cancer</i> , 2018 , 117, 1-6	5.9	34
25	U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2020 , 26, 4785-4794	12.9	29
24	Cell-permeable carboxyl-terminal p27(Kip1) peptide exhibits anti-tumor activity by inhibiting Pim-1 kinase. <i>Journal of Biological Chemistry</i> , 2011 , 286, 2681-8	5.4	24
23	TUSC4/NPRL2, a novel PDK1-interacting protein, inhibits PDK1 tyrosine phosphorylation and its downstream signaling. <i>Cancer Science</i> , 2008 , 99, 1827-34	6.9	24
22	Modulation of Wnt signaling by the nuclear localization of cellular FLIP-L. <i>Journal of Cell Science</i> , 2010 , 123, 23-8	5.3	22
21	Therapeutic strategies and mechanisms of drug resistance in anaplastic lymphoma kinase (ALK)-rearranged lung cancer. <i>Pharmacology & Therapeutics</i> , 2017 , 177, 1-8	13.9	21
20	Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms. <i>Cancer Science</i> , 2020 , 111, 932-939	6.9	20
19	Impairment of the ubiquitin-proteasome system by cellular FLIP. <i>Genes To Cells</i> , 2007 , 12, 735-44	2.3	18
18	Targeting the Golgi apparatus to overcome acquired resistance of non-small cell lung cancer cells to EGFR tyrosine kinase inhibitors. <i>Oncotarget</i> , 2018 , 9, 1641-1655	3.3	16
17	Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 915-925	8.9	15
16	Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer. <i>Nature Communications</i> , 2021 , 12, 1261	17.4	14
15	Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 752-765	8.9	12
14	Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer. <i>Thoracic Cancer</i> , 2020 , 11, 581-587	3.2	11
13	Cell differentiation inducers derived from thalidomide. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005 , 15, 3212-5	2.9	11
12	TKI-addicted ROS1-rearranged cells are destined to survival or death by the intensity of ROS1 kinase activity. <i>Scientific Reports</i> , 2017 , 7, 5519	4.9	7
11	Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity. <i>Npj Precision Oncology</i> , 2021 , 5, 32	9.8	6
10	Monitoring epidermal growth factor receptor C797S mutation in Japanese non-small cell lung cancer patients with serial cell-free DNA evaluation using digital droplet PCR. <i>Cancer Science</i> , 2021 , 112, 2371-2380	6.9	5
9	Improvement in predicting drug sensitivity changes associated with protein mutations using a molecular dynamics based alchemical mutation method. <i>Scientific Reports</i> , 2020 , 10, 2161	4.9	4

8	A safety study of newly generated anti-podoplanin-neutralizing antibody in cynomolgus monkey (). <i>Oncotarget</i> , 2018 , 9, 33322-33336	3.3	4
7	Novel knock-in mouse model for the evaluation of the therapeutic efficacy and toxicity of human podoplanin-targeting agents. <i>Cancer Science</i> , 2021 , 112, 2299-2313	6.9	3
6	3D culture system containing gellan gum restores oncogene dependence in ROS1 rearrangements non-small cell lung cancer. <i>Biochemical and Biophysical Research Communications</i> , 2018 , 501, 527-533	3.4	3
5	Efficacy of EGFR tyrosine kinase inhibitors in patients having EGFR-activating mutations with or without BIM polymorphisms. <i>Cancer Chemotherapy and Pharmacology</i> , 2020 , 86, 517-525	3.5	2
4	A case of hyperprogressive disease following atezolizumab therapy for pulmonary pleomorphic carcinoma with epidermal growth factor receptor mutation. <i>Respiratory Medicine Case Reports</i> , 2021 , 33, 101405	1.2	2
3	Platelet-derived lysophosphatidic acid mediated LPAR1 activation as a therapeutic target for osteosarcoma metastasis. <i>Oncogene</i> , 2021 , 40, 5548-5558	9.2	2
2	GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancer.. <i>Npj Precision Oncology</i> , 2022 , 6, 16	9.8	1
1	HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features.. <i>Npj Precision Oncology</i> , 2022 , 6, 5	9.8	0